U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C13H17N3O3S2
Molecular Weight 327.422
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GLYSOBUZOLE

SMILES

COC1=CC=C(C=C1)S(=O)(=O)NC2=NN=C(CC(C)C)S2

InChI

InChIKey=LZCBNYVJTNCPDR-UHFFFAOYSA-N
InChI=1S/C13H17N3O3S2/c1-9(2)8-12-14-15-13(20-12)16-21(17,18)11-6-4-10(19-3)5-7-11/h4-7,9H,8H2,1-3H3,(H,15,16)

HIDE SMILES / InChI

Description

Glysobuzole (stabinol) is a sulfonamide derivative with antihyperglycemic activity. Like sulfonylureas, glysobuzole is able to lower blood glucose levels by increasing the release of insulin from pancreatic beta cells.

Originator

Horner
3

Approval Year

Unknown
139,594

Targets

Primary TargetPharmacologyConditionPotency
insulin metabolic process
1
Modulator
828

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diabetes mellitus
91
 Primary
Not Provided
504
Unknown

PubMed

Patents

US20070116729
21
US20070122474
1
US6680047B2
5

Sample Use Guides

In Vivo Use Guide
Diabetes patients were started on four tablets of 250 mg (1 g) of stabinol (given in a single dose in the morning).
Route of Administration: Oral
In Vitro Use Guide
Unknown
ACTIVE MOIETY
Structure of GLYSOBUZOLE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966